Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1)
Activated PI3K delta syndrome is a rare primary combined immunodeficiency that can present with lymphoma. Genetic testing of patients with atypical lymphoma may reveal an underlying immunodeficiency and improve clinical outcomes.
Saved in:
| Main Authors: | Alex Wonnaparhown, MD, Matthew Farley, MD, Holly Miller, DO, Charlotte Cunningham-Rundles, MD, Catherine Freeman, MBBCh, Jacqueline Squire, MD, Talal Hilal, MD, Allison Rosenthal, DO |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829325001043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS)
by: Malena Mahendran, et al.
Published: (2025-05-01) -
The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus
by: Jeong Hyo Lee, et al.
Published: (2025-07-01) -
EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review
by: Qiu-yuan Xiang, et al.
Published: (2025-05-01) -
Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers
by: Yinhao Chen, et al.
Published: (2025-04-01) -
Correction: EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review
by: Qiu-yuan Xiang, et al.
Published: (2025-07-01)